MedPath

Probiotics in Preventing Antibiotic Associated Diarrhoea Including Clostridium Difficile Infection

Not Applicable
Completed
Conditions
Clostridium Difficile
Diarrhoea
Interventions
Dietary Supplement: Probiotic drink containing the live strain
Dietary Supplement: placebo probiotic
Registration Number
NCT01087892
Lead Sponsor
University of Sussex
Brief Summary

Antibiotics are currently required to treat patients in hospital when they have an infection, but these antibiotics can cause side effects such as diarrhoea and in some patients a serious form of gut infection with an organism called Clostridium difficile. This organism can produce toxins in the gut causing a severe form of diarrhoea associated with a lot of ill health, and in some circumstances can be fatal. Some studies have shown that yogurts' or Probiotics' (special drinks with a defined concentration of useful bacteria) taken by patients can have a beneficial effect in reducing the diarrhoea associated with antibiotics use. The aim of the present study is to find out whether the use of one of these Probiotics in hospitalised patients taking antibiotics will result in less diarrhoea, less Clostridium difficile infection, as well as cost saving. The study will also analyze the effects of probiotics on quality of life and length of hospital stay.

Detailed Description

As part of this study, we will look at both microbiological and immunological markers, in addition to analyzing the overall cost implications by analysis of health economics.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1126
Inclusion Criteria
  • Male/female patients, above 55 years of age Patient has given written informed consent/Assent to take part in the study Patients are receiving antibiotics as inpatients Patients prescribed therapy with single or multiple antibiotics (oral or IV) will be included Antibiotic therapy must be indicated for a minimum of 72 hours Patients must be able to take medication orally Inclusion in the study is approved by the admitting consultant and validated by a member of the trial team within 48 hours
Exclusion Criteria
  • Age less than 55 years Pregnancy Patients on PEG feed. Diarrhoea on admission or within the preceding week Severe life-threatening illness

Subjects with allergy or hypersensitivity to any component of the study product (e.g.: allergy or hypersensitivity to milk proteins) Subjects who had any surgery or intervention in the last 4 weeks Subjects enrolled in another clinical study in the last 4 weeks Subjects who are thought not to comply with the clinical study Subjects presenting with a severe evolving or active pathology or infection of the gastrointestinal tract such as inflammatory bowel disease, Crohn's disease or ulcerative colitis, diverticular disease or liver cirrhosis.

Any condition affecting the pancreas including acute and chronic pancreatitis Patients who had a surgical operation in their bowels in the preceding 3 months A medical condition such that the life expectancy of the patient is predicted at less than 3 months by the admitting consultant and validated by a member of the trial team Immune-suppressed patients (e.g. HIV) Steroid use of Prednisolone greater than 10mg a day (or equivalent of Dexamethasone) for over 2 weeks prior to entering the trial Patients on Cytotoxic drugs Post-transplant patients Any clinical condition affecting the pancreas including acute and chronic pancreatitis Patients with prosthetic heart valves or a history of endocarditis. Patients who have taken probiotic drinks containing live organisms or over the counter probiotic preparations in the past seven days (see Appendix 10) Foreign travel in the last 7 days

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Dietary supplement Probiotic drinkProbiotic drink containing the live strainDouble blind Probiotic containing the live strain 100g/day orally, twice daily for the duration of the course of antibiotics plus seven days
Dietary supplement probiotic placebo drinkplacebo probioticDouble blind 'placebo' is actually a control product Placebo drink contains no strain 100gs orally, twice daily for the duration of the course of antibiotics plus seven days
Primary Outcome Measures
NameTimeMethod
The incidence of diarrhoearegular intervals for 28days from entry to trial

The incidence of antibiotic associated diarrhoea in the active and placebo group by the end of the follow up period

Secondary Outcome Measures
NameTimeMethod
incidence and duration of Clostridium difficile toxinregular intervals for 28 days from entry to trial

The incidence and duration of Clostridium difficile toxin detected by ELISA positive testing from a stool sample taken at the onset of diarrhoea in the active and placebo groups

The rate of recurrence of antibiotic associated diarrhoea in the active and placebo groups to the end of the follow up periodregular intervals for 28 days from entry to trial

The rate of recurrence of antibiotic associated diarrhoea in the active and placebo groups to the end of the follow up period

rate of recurrence of Clostridium difficile toxin positive diarrhoearegular intervals for 28 days from entry to trial

The rate of recurrence of Clostridium difficile toxin positive diarrhoea in the active and placebo groups from hospital discharge until the end of the follow-up period

The quality of life in the active and placebo groups at enrollment into the studyregular intervals for 28 days from entry to trial
The length of hospital stay from enrollment into the study until the end of the follow up period in the active and placebo groups The cost-effectiveness as evidenced by health economic calculationsregular intervals for 28 days from entry to trial

Trial Locations

Locations (26)

Blackpool Vicotria Hospital

πŸ‡¬πŸ‡§

Blackpool, United Kingdom

Cambridge University Hospital Trust

πŸ‡¬πŸ‡§

Cambridge, United Kingdom

Ealing Hospital

πŸ‡¬πŸ‡§

Ealing, United Kingdom

Eastbourne District General Hospital

πŸ‡¬πŸ‡§

Eastbourne, United Kingdom

Hillingdon Hospital

πŸ‡¬πŸ‡§

Hillingdon, United Kingdom

Lancashire Teaching Hospital

πŸ‡¬πŸ‡§

Lancaster, United Kingdom

University Hosppitals of Leicester

πŸ‡¬πŸ‡§

Leicester, United Kingdom

Lewisham Helathcare NHS Trust

πŸ‡¬πŸ‡§

Lewisham, United Kingdom

St Georges Hospital London

πŸ‡¬πŸ‡§

London, United Kingdom

Queen Elizabeth Queen Mother Hospital

πŸ‡¬πŸ‡§

Margate, United Kingdom

Kings College Hospital

πŸ‡¬πŸ‡§

London, United Kingdom

Ashford and St Peters Hospital

πŸ‡¬πŸ‡§

Ashford, United Kingdom

Royal Sussex County Hospital

πŸ‡¬πŸ‡§

Brighton, United Kingdom

Broomfield Hospital

πŸ‡¬πŸ‡§

Chelmsford, United Kingdom

St.Richards Hospital

πŸ‡¬πŸ‡§

Chichester, United Kingdom

Colchester Hospitals University

πŸ‡¬πŸ‡§

Colchester, United Kingdom

Frimley Park Hospital

πŸ‡¬πŸ‡§

Frimley, United Kingdom

Princess Royal Hospital

πŸ‡¬πŸ‡§

Haywards Heath, United Kingdom

Yeovil District Hospital

πŸ‡¬πŸ‡§

Yeovil, United Kingdom

Norfolk and Norwich University

πŸ‡¬πŸ‡§

Norwich, United Kingdom

University Hospitals of Morecambe Bay

πŸ‡¬πŸ‡§

Morecambe, United Kingdom

Portsmouth Hospitals NHS Trust

πŸ‡¬πŸ‡§

Portsmouth, United Kingdom

Worcestershire Acute Hospitals

πŸ‡¬πŸ‡§

Redditch, United Kingdom

East Surrey Hospital

πŸ‡¬πŸ‡§

Redhill, United Kingdom

University Hospital Southampton

πŸ‡¬πŸ‡§

Southampton, United Kingdom

Maidstone and Tunbridge Wells NHS Trust

πŸ‡¬πŸ‡§

Tunbridge Wells, United Kingdom

Β© Copyright 2025. All Rights Reserved by MedPath